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Background: Randomised controlled trials (RCTs) provide the most reliable information to inform clinical practice
and patient care. We aimed to map global clinical research publication activity through RCT-related articles in high-
impact-factor medical journals over the past five decades.
Methods: We conducted a cross-sectional analysis of articles published in the highest ranked medical journals with
an impact factor > 10 (according to Journal Citation Reports published in 2017). We searched PubMed/MEDLINE
(from inception to December 31, 2017) for all RCT-related articles (e.g. primary RCTs, secondary analyses and
methodology papers) published in high-impact-factor medical journals. For each included article, raw metadata
were abstracted from the Web of Science. A process of standardization was conducted to unify the different terms
and grammatical variants and to remove typographical, transcription and/or indexing errors. Descriptive analyses
were conducted (including the number of articles, citations, most prolific authors, countries, journals, funding
sources and keywords). Network analyses of collaborations between countries and co-words are presented.
Results: We included 39,305 articles (for the period 1965–2017) published in forty journals. The Lancet (n = 3593;
9.1%), the Journal of Clinical Oncology (n = 3343; 8.5%) and The New England Journal of Medicine (n = 3275 articles;
8.3%) published the largest number of RCTs. A total of 154 countries were involved in the production of articles.
The global productivity ranking was led by the United States (n = 18,393 articles), followed by the United Kingdom
(n = 8028 articles), Canada (n = 4548 articles) and Germany (n = 4415 articles). Seventeen authors who had published
100 or more articles were identified; the most prolific authors were affiliated with Duke University (United States),
Harvard University (United States) and McMaster University (Canada). The main funding institutions were the
National Institutes of Health (United States), Hoffmann-La Roche (Switzerland), Pfizer (United States), Merck Sharp &
Dohme (United States) and Novartis (Switzerland). The 100 most cited RCTs were published in nine journals, led by
The New England Journal of Medicine (n = 78 articles), The Lancet (n = 9 articles) and JAMA (n = 7 articles). These
landmark contributions focused on novel methodological approaches (e.g. the “Bland-Altman method”) and trials
on the management of chronic conditions (e.g. diabetes control, hormone replacement therapy in postmenopausal
women, multiple therapies for diverse cancers, cardiovascular therapies such as lipid-lowering statins,
antihypertensive medications, and antiplatelet and antithrombotic therapy).
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Conclusions: Our analysis identified authors, countries, funding institutions, landmark contributions and high-
impact-factor medical journals publishing RCTs. Over the last 50 years, publication production in leading medical
journals has increased, with Western countries leading in research but with low- and middle-income countries
showing very limited representation.
Keywords: Evidence-based medicine, Randomized controlled trial, Scientific collaborationBackground
Randomised controlled trials (RCTs) are considered one
of the simplest and most powerful tools for assessing the
safety and effectiveness of treatment interventions [1–3].
When appropriately designed, conducted and reported,
RCTs can produce an immediate impact on clinical
practice and patient care [4].
The evolution of RCTs has been an enduring and
continuing process [5–15]. Since the 1970s the publica-
tion landscape for RCTs has exhibited an exponential
growth. For example, a 1965–2001 bibliometric analysis
of the literature identified 369 articles published in 1970
compared to 11,159 published in 2000 [5]. The develop-
ment of clinical trial registries (such as clinicaltrials.gov)
[9, 10], the exponential increase in journals publishing
trial protocols, results and secondary studies, and grow-
ing support for data-sharing policies [11, 12] have cre-
ated an open research environment of transparency and
accountability. Furthermore, the publication of reporting
guidelines (such as CONSORT and SPIRIT) [4, 13–15]
have served to facilitate the transition between research
and reporting to ensure standardisation and ease of
readability.
RCTs published in major medical journals are highly
cited and have an instrumental role in clinical practice
and health policy decisions [5, 16, 17]. Previous studies
have focused on the quality of the reporting of methods
and results of RCTs [18–22] and publication practices
[23–28] in selected samples of articles published in
high-impact-factor (IF) medical journals. However, to
the best of our knowledge, no mapping studies have
been conducted on major medical journals to investigate
the most common subjects, most productive scientists
and countries, most prolific journals and “citation clas-
sics” across multiple specialties.
The objective of this study was to describe and charac-
terise the global clinical research publication activity
through RCT articles published in high-IF medical jour-
nals during the past decades.Methods
Eligibility criteria
This cross-sectional analysis investigated RCT-related
articles (that is, primary RCTs, secondary analyses and
methodology papers using clinical data) published inmajor medical journals. We excluded narrative reviews,
systematic reviews, meta-analyses, pool-analyses, letters
and newspaper articles. All RCT-related articles indexed
in PubMed/MEDLINE had to be published in one of the
major medical journals with an IF exceeding 10 (2016 IF
according to the Journal Citation Reports [JCR] pub-
lished in June 2017). These medical journals were
chosen because they were identified as publishing clin-
ical research with scientific merit and clinical relevance
(see Table 1 for a list of the included medical journals).
Search
On March 22, 2018, we systematically searched MED-
LINE through PubMed (National Library of Medicine,
Bethesda, MD, United States) for all RCT-related articles
published in high-IF medical journals (from inception to
December 31, 2017). A senior information specialist
(AA-A) and a clinical epidemiologist (FC-L) designed an
electronic literature search using a validated research
methodology filter for RCTs (with 97% specificity and
93% sensitivity) [29]. The search was peer reviewed by
members of the study team, including a second (senior)
information specialist (RA-B). The full search strategy is
provided in Additional file 1. On May 7, 2018, we
searched the Web of Science (WoS) (Clarivate Analytics,
Philadelphia, Penn., United States) by using PubMed IDs
(PMIDs) from the PubMed/MEDLINE searches. Mer-
ging MEDLINE with other citation indices such as the
WoS combines the advantages of MEDLINE (e.g., Med-
ical Subject Headings [MeSH], a comprehensive con-
trolled vocabulary for indexing journal articles) with the
relational capabilities and data of the WoS [30].
Data extraction and normalisation
For each included article, raw (meta) data on the journal
and article titles, subject category, the year of publica-
tion, keywords, and the authors’ names, institutional
affiliation(s), funding source, and country was down-
loaded online through the WoS by one researcher (A-
AA). We also used the WoS to determine the extent to
which each article had been cited in the scientific peer-
review literature using the “times cited” number (that is,
the number of times a publication has been cited by
other publications). Two researchers (FC-L, RA-B) inde-
pendently verified the data to minimise potential
Table 1 Included high-impact-factor medical journals
General medicine journals (with an IF > 10):
- The New England Journal of Medicine (IF = 72.406)
- The Lancet (IF = 47.831)
- JAMA – the Journal of the American Medical Association (IF = 44.405)
- The BMJ – the British Medical Journal (IF = 20.785)
- Annals of Internal Medicine (IF = 17.202)
- JAMA Internal Medicine – formerly, Archives of Internal Medicine
(IF = 16.538)
- PLOS Medicine (IF = 11.862)
Medical specialty journals (with an IF > 10):
- Lancet Oncology (IF = 33.900)
- World Psychiatry (IF = 26.561)
- Lancet Neurology (IF = 26.284)
- Journal of Clinical Oncology (IF = 24.008)
- European Heart Journal (IF = 20.212)
- JACC – Journal of the American College of Cardiology (IF = 19.896)
- Lancet Infectious Diseases (IF = 19.864)
- Lancet Diabetes & Endocrinology (IF = 19.742)
- Circulation (IF = 19.309)
- Lancet Respiratory Medicine (IF = 19.287)
- Gastroenterology (IF = 18.392)
- Gut (IF = 16.658)
- JAMA Oncology (IF = 16.559)
- European Urology (IF = 16.265)
- JAMA Psychiatry – formerly, Archives of General Psychiatry
(IF = 15.307)
- American Journal of Psychiatry (IF = 14.176)
- Circulation Research (IF = 13.965)
- Hepatology (IF = 13.246)
- American Journal of Respiratory and Critical Care Medicine
(IF = 13.204)
- Blood (IF = 13.164)
- Journal of Allergy and Clinical Immunology (IF = 13.081)
- Annals of the Rheumatic Diseases (IF = 12.811)
- JNCI – Journal of the National Cancer Institute (IF = 12.589)
- Journal of Hepatology (IF = 12.486)
- Intensive Care Medicine (IF = 12.015)
- Diabetes Care (IF = 11.857)
- Annals of Oncology (IF = 11.855)
- Leukaemia (IF = 11.702)
- Lancet Psychiatry (IF = 11.588)
- European Respiratory Journal (IF = 10.569)
- Brain (IF = 10.292)
- JAMA Pediatrics – formerly, Archives of Pediatrics & Adolescent
Medicine (IF = 10.251)
- JAMA Neurology – formerly, Archives of Neurology (IF = 10.029)
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ducted by two researchers to bring together the different
names of an author or country and the keywords (fur-
ther details are available in Additional file 2). Specific-
ally, one researcher (AA-A) checked the names by which
an individual author appeared in two or more different
forms (for example, “John McMurray” or “John J.
McMurray” or “John J.V. McMurray”) using coincidence
in that author’s place(s) of work as the basic criterion for
normalisation (for example, University of Glasgow,
Scotland, United Kingdom) [31], and a second re-
searcher (FC-L or RA-B) verified the data. A threshold
of 30 articles was applied to review 200 names by which
an individual author appeared in two or more different
forms.
We extracted both “author keywords” and “keyword
plus,” which are automatically assigned by the WoS from
the titles of the references of the articles, as topical (also
called textural, linguistic or sematic) data [32]. To ensure
consistency in the data, one researcher (RA-B) corrected
keywords by unifying grammatical variants and using only
one keyword developed to name the same concept (for ex-
ample, “randomized trial” or “randomized clinical trial” or
“randomized controlled trial” or “randomised controlled
trial”). In addition, the same researcher (RA-B) removed
typographical, transcription and/or indexing errors, and a
second researcher (FC-L) verified the data. All potential
discrepancies were resolved via consensus amongst these
investigators. All these data were collected and entered
into a Microsoft Access® (Microsoft, Seattle, WA, United
States) database between May 7, 2018, and January 9,
2019.
Data analysis
We analysed data for the number of articles, citations,
signatures (or total number of authors included in all
the articles of each author), collaboration index (that is
the mean number of author’s signatures per article),
countries, journals and keywords. Data were summarised
as frequencies and percentages for the categorical items.
The most prolific authors (>100 articles), countries
(>100 articles), funding institutions (>100 articles), and
the most cited papers (“top-100 citation classics”) were
identified. Network plots were generated for intense
scientific collaboration between countries (applying a
threshold of 100 articles in collaboration).
We conducted an exploratory analyses of topical data
using a set of unique keywords and their frequencies to
examine the topic coverage, major topics (“word clouds”
of keywords) and their interrelations (“co-words net-
works”) in RCT articles. The main goal in topical ana-
lyses is to understand the topical distribution of a
dataset, i.e. what topics are covered and how much of
each topic is covered in a scientific discipline [32]. The
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most prolific journals (with at least 1000 articles). Based
on the most frequently used keywords (with at least 500
articles), a word cloud was created from text that the
user provides and more emphasis was placed on words
that appear with greater frequency in the source text. A
“co-words network” was created to illustrate the co-
occurrence of highly frequent words in the articles (ap-
plying a threshold of 100 articles in collaboration). The
network analysis was carried out with the use of PAJEK
(University of Ljubljana, Slovenia) [33], a software pack-
age for large network analysis that is free for non-
commercial use to construct network graphs. The PRISMA
checklist [34] (http://www.prisma-statement.org/) guided
the reporting of the present analysis (and is available in
Additional file 3).
Results
A total of 39,329 records were identified by the
PubMed/MEDLINE search (Fig. 1), and 39,305 articles
met the study inclusion criteria (Additional file 4) after
24 records had been excluded (Additional file 5). Table 2
details the general characteristics of the articles.
Publication trend
The number of articles increased exponentially over the
period 1965–2017 (Fig. 2). Approximately 60% (n = 23,
635) of the articles have been published since 2000.Fig. 1 Flow diagram with selection of articlesJournals and subject category
Forty journals published 39,305 articles, and 23.8% of
them (n = 9355) were published by four journals with an
IF > 30. The Lancet (9.1%; n = 3593), the Journal of Clin-
ical Oncology (8.5%; n = 3343) and The New England
Journal of Medicine (8.3%; n = 3275) published the lar-
gest number of articles, followed by The BMJ (6.4%; n =
2516) and Circulation (5.9%; n = 2331). Most articles
were classified as “medicine, general & internal” (30.7%;
n = 13,688); “cardiac & cardiovascular systems” (13.1%;
n = 5828); or “oncology” (12.9%; n = 5760) according to
the WoS journal categorisations (Table 2).
Authors, institutions and countries
Most articles (62.3%; n = 24,496) were written by seven
or more authors, and only 11.4% (n = 4469) of the arti-
cles were written by three or fewer authors. The first au-
thors of the articles were based most commonly in
North America and Western Europe; first authors from
the United States were responsible for 36.9% (n = 14,
508) of the articles (Table 2). We identified 17 authors
who published 100 or more articles (Table 3). All of the
most productive authors were male. The most prolific
authors were Robert M. Califf, with 239 articles (from
Duke University, United States); Eugene Braunwald, with
218 (from Harvard University, United States); Salim
Yusuf, with 217 (from McMaster University, Canada);
Eric J. Topol, with 212 (from Scripps Translational
Table 2 General characteristics of the study sample
Characteristic Number Percent
Total number of articles 39,305 100.0
Journal (top-10)
The Lancet 3593 9.1
Journal of Clinical Oncology 3343 8.5
The New England Journal of Medicine 3275 8.3
The BMJ 2516 6.4
Circulation 2331 5.9
JACC Journal of the American College of Cardiology 2133 5.4
JAMA 1904 4.8
Diabetes Care 1885 4.8
Journal of Allergy and Clinical Immunology 1345 3.4
European Heart Journal 1315 3.3
Year of publication
Before 1980 2004 5.1
1980–1989 4040 10.3
1990–1999 9626 24.5
2000–2009 12,574 32.0
2010–2017 11,061 28.1
Journal impact factor (2016)
10.0–15.0 12,150 30.9
15.1–20.0 10,388 26.4
20.1–25.0 7174 18.3
25.1–30.0 238 0.6
>30.0 9355 23.8
Main subject categorya
Medicine, General & Internal 13,688 30.7
Cardiac & Cardiovascular Systems 5828 13.1
Oncology 5760 12.9
Gastroenterology & Hepatology 3023 6.8
Psychiatry 2380 5.3
Number of citations
0–50 15,449 39.3
51–100 8714 22.2
101–500 13,056 33.2
501–1000 1445 3.7
>1000 641 1.6
Number of authors
1 1064 2.7
2–3 3405 8.7
4–6 10,340 26.3
7–10 11,142 28.3
>10 13,354 34.0
Country of first author (top-10)
United States 14,508 36.9
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Table 2 General characteristics of the study sample (Continued)
Characteristic Number Percent
United Kingdom 4924 12.5
The Netherlands 1874 4.8
Germany 1862 4.7
Canada 1847 4.7
France 1732 4.4
Italy 1720 4.4
Australia 999 2.5
Sweden 755 1.9
Denmark 660 1.7
Source of funding
Reported 16,485 41.9
None/not reported 22,820 58.1
aSubject category according to Journal Citation Reports (JCR)
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186 (from University of Auckland, New Zealand); Lars
Wallentin, with 144 (Uppsala University, Sweden); and
Christopher B. Granger, with 140 (from Duke University,
United States).
Overall, 154 countries worldwide contributed to the
analysed articles. The publication productivity ranking
for countries (Table 4) was led by the United States (n =
18,393 articles, with 3.4 million citations), followed by
the United Kingdom (n = 8028 articles, with 1.3 million
citations), Canada (n = 4548 articles, with 1.0 million ci-
tations) and Germany (n = 4415 articles, with 0.9 million
citations). A total of 37 countries had at least 100 articles
in co-authorship. Figure 3 shows a visual representation
of the most intense collaborative network between these
37 countries, in which we can see the relationships ofFig. 2 Number of articles by year of publicationsome countries with respect to others and the position
that each occupies in the network.
Funding source
A total of 16,485 articles (41.9%) reported sources of
funding. The 40 most frequent funding institutions (with
100 or more articles) are listed in Table 5. The main
funders were the National Institutes of Health (NIH),
with 7422 articles; Hoffmann-La Roche (n = 1188), Pfizer
(n = 1139), Merck Sharp & Dohme (n = 1097) and
Novartis (n = 1052).
Most cited articles
Overall, included articles received 5.9 million citations,
of which 83.1% of the citations (n = 4,950,604) corre-
sponded to 15,142 (38.5%) articles with more than 100
Table 3 Most productive authors and their institutions
Author Affiliation and country Articles Citations Citations
per article
Articles in
collaboration
Total
signatures
Collaboration index
(signatures per article)
Califf, Robert M. Duke Clinical Research Institute, Duke
University, United States
239 56,742 237.4 239 7919 33.1
Braunwald, Eugene Brigham and Women’s Hospital,
Harvard University, United States
218 63,764 292.5 218 8296 38.1
Yusuf, Salim McMaster University, Canada 217 79,270 365.3 216 9163 42.4
Topol, Eric J. Scripps Translational Science Institute,
United States
212 48,523 228.9 212 6229 29.4
White, Harvey D. Auckland City Hospital, University of
Auckland, New Zealand
186 38,540 207.2 185 9133 49.4
Wallentin, Lars Uppsala Clinical Research Centre,
Uppsala University, Sweden
144 32,741 227.4 142 2958 20.8
Granger, Christopher B. Duke Clinical Research Institute, Duke
University, United States
140 29,668 211.9 140 5025 35.9
Stone, Gregg W. New York-Presbyterian Hospital,
Columbia University, United States
135 24,601 182.2 135 1928 14.3
Serruys, Patrick W. Imperial College London, United
Kingdom and
Erasmus University, The Netherlands
133 27,302 205.3 133 2253 16.9
Armstrong, Paul W. University of Alberta Hospital,
University of Alberta, Canada
125 25,992 207.9 124 4573 36.9
McMurray, John J.V. University of Glasgow, Scotland,
United Kingdom
116 30,470 262.7 116 3425 29.5
Pfeffer, Marc A. Brigham and Women’s Hospital,
Harvard University, United States
116 46,032 396.8 115 4070 35.4
Gelber, Richard D. Dana-Farber Cancer Institute, Harvard
University, United States
107 20,898 195.3 107 3311 30.9
Van de Werf, Frans Catholic University of Leuven,
University Hospital Leuven, Belgium
107 21,918 204.8 105 4492 42.8
Harrington, Robert A. Stanford University, United States 105 20,436 194.6 103 4971 48.3
Cannon, Christopher P. Brigham and Women’s Hospital,
Harvard University, United States
103 26,192 254.3 103 2241 21.8
Goldhirsch, Aron European Institute of Oncology, Italy 103 16,254 157.8 98 3279 33.5
Note: Top authors with at least 100 articles
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than 1000 citations accounted for 20.7% of the total cita-
tions (n = 1,234,462). The most cited articles by number
of citations (“100 citation classics”) are listed in Table 6.
All of the most cited papers were published in English.
These most cited articles were published in nine jour-
nals, led by The New England Journal of Medicine, with
78 articles, followed by The Lancet (n = 9) and JAMA
(n = 7). The list of most cited papers contained innova-
tive research methodologies. For example, the most cited
article was a method paper published in The Lancet
(“Bland-Altman method”) [35]. This seminal paper chan-
ged how method comparison studies are performed in
clinical research. The list of the most cited papers also
reflected important studies examining the health effects
of pharmacological interventions on patients with
chronic diseases. Common themes in major advances in
health interventions included diabetes control [36–41];the effects of hormone replacement therapy in postmen-
opausal women [42, 43]; therapies for diverse cancers
such as glioblastoma, colorectal cancer, breast cancer,
melanoma and hepatocellular carcinoma [44–50]; im-
portant interventional studies in the field of clinical car-
diology, such as lipid-lowering statin therapy trials,
antihypertensive trials, and antiplatelet and/or anti-
thrombotic trials [51–63].
Common keywords
The most commonly used article keywords were “clinical
trial” (16.1%; n = 6332 papers), followed by “therapy”
(10.8%; n = 4267), “randomised controlled trial” (6.6%;
n = 2587), “chemotherapy” (5.6%; n = 2224), “risk” (5.1%;
n = 2026), “efficacy” (4.9%; n = 1933) and “double-blind”
(4.9%; n = 1929). The most frequently used keywords in
the most prolific journals are shown in Table 7. In
addition, exploratory analyses of word clouds and
Table 4 Productivity and patterns of collaboration by top countries
Country Total
articles
Articles per
million
inhabitants
Total
collaborations
Total
citations
Citations
per article
Articles in
collaboration
(distinct country)
Distinct
countries of
collaboration
Main collaborator (and
number of
collaborations)
United States 18,393 56.5 25,308 3,364,015 182.9 7895 130 Canada (2892)
United Kingdom 8028 121.6 18,529 1,345,597 167.6 4534 128 United States (2528)
Canada 4548 123.9 13,024 1,017,912 223.8 3552 108 United States (2892)
Germany 4415 53.4 16,463 894,026 202.5 3416 111 United States (2034)
France 3900 58.1 15,093 826,172 211.8 2928 119 United States (1759)
Italy 3608 59.6 13,005 674,367 186.9 2432 96 United States (1446)
The Netherlands 3453 201.5 10,578 619,589 179.4 2331 99 United States (1172)
Australia 2354 95.7 8787 469,341 199.4 1750 103 United States (1114)
Belgium 2197 193.2 10,685 482,974 219.8 2016 107 United States (1068)
Spain 2020 43.4 9747 417,291 206.6 1581 99 United States (1017)
Sweden 1909 189.6 7034 376,159 197.0 1483 91 United States (794)
Switzerland 1862 219.9 7840 348,734 187.3 1621 117 United States (818)
Denmark 1523 264.0 5572 297,936 195.6 1090 84 United States (582)
Poland 953 25.1 6577 222,301 233.3 916 80 United States (650)
Austria 945 107.3 4673 192,799 204.0 832 85 Germany (555)
Japan 820 6.5 2232 132,758 161.9 374 66 United States (289)
Finland 797 144.6 2950 195,500 245.3 556 81 United States (264)
China 771 0.6 3292 141,741 183.8 550 87 United States (391)
Norway 756 143.1 3076 152,184 201.3 605 70 Sweden (310)
Israel 661 75.9 3364 159,264 240.9 547 71 United States (382)
Brazil 626 3.0 4102 154,296 246.5 567 98 United States (440)
New Zealand 602 125.6 2229 106,318 176.6 480 80 United States (293)
Czech Republic 486 45.9 3757 107,543 221.3 475 82 United States (315)
South Korea 474 9.2 2748 80,338 169.5 383 78 United States (322)
South Africa 463 8.2 2468 89,382 193.0 422 95 United States (311)
Russia 425 2.9 3449 109,224 257.0 424 75 United States (336)
Greece 419 38.9 2114 59,496 142.0 285 75 United States (168)
Hungary 392 40.1 3192 93,590 238.7 383 74 United States (249)
Argentina 390 8.8 2736 117,289 300.7 357 91 United States (290)
India 370 0.3 2016 63,646 172.0 299 101 United States (214)
Taiwan 341 14.5 1803 77,089 226.1 242 63 United States (194)
Ireland 297 61.7 1366 60,867 204.9 263 79 United Kingdom (170)
Mexico 253 2.0 1754 56,256 222.4 230 84 United States (195)
Singapore 194 34.6 1210 42,265 217.9 176 80 United States (120)
Turkey 189 2.3 1288 34,928 184.8 149 79 United States (92)
Thailand 185 2.7 1268 55,360 299.2 177 93 United States (120)
Portugal 168 16.3 1218 24,177 143.9 160 61 Belgium (89), France (89)
Chile 157 8.7 1265 37,556 239.2 149 81 United States (112)
Romania 149 7.6 1406 31,392 210.7 148 77 United States (110)
Ukraine 113 2.5 1007 29,880 264.4 113 61 United States (84)
Uganda 112 2.6 405 14,931 133.3 108 72 United States (78)
Kenya 107 2.2 508 18,737 175.1 103 83 United States (68)
Note: Top countries with at least 100 articles. Country inhabitants (year 2017) obtained from the World Bank (http://data.worldbank.org/)
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Fig. 3 Global collaborative network between countries. Note: Most productive cluster of countries applying a threshold of 100 or more papers
signed in co-authorship. Node sizes are proportional to the number of papers, and line thicknesses are proportional to the number of
collaborations. Node colours: America = red; Asia = yellow; Africa = green; Europe = blue; Oceania = purple
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broad range of the topics covered (see Additional file 6).
Discussion
In this cross-sectional analysis, we presented a global
mapping of RCT-related articles published in high-IF
medical journals for the period 1965–2017. We identi-
fied the most prolific scientists, institutions and countries,
main funding sources, most common subjects and topics,
“citation classics” and most prolific high-IF medical jour-
nals from multiple specialties over the last 50 years.
In general, we found a strong clustering of articles
published in British and American medical journals (The
Lancet, Journal of Clinical Oncology, The New England
Journal of Medicine, The BMJ, Circulation, JAMA, JACC
and Diabetes Care accounted for 53% of the RCT-
related articles). Many of these journals have been devel-
oped by active medical associations, both nationally and
internationally. We hypothesize that different publishing
patterns between journals may potentially reflect editor-
ial policies and/or preferences, with some general medi-
cine journals (such as The Lancet and The New England
Journal of Medicine) and specialty journals (such as Jour-
nal of Clinical Oncology and Circulation), being more in-
terested in and/or promoting the publication of RCTs.
In contrast, a substantial number of these articles are be-
hind publication paywalls (very few of the medicaljournals in our study sample are Open Access), and thus,
research results may not be accessible to a large fraction
of the scientific community and society as a whole,
including clinicians (and patients) who may want them
to help inform their clinical practice.
The results of this study highlight the expanding
collaborative networks between countries in multiple re-
gions, revealing a discernible scientific community, with
the most productive countries having an important
number of collaborations. Publication activity efforts
were global during the study period, with articles from
scientists and institutions in more than 150 different
countries. However, the scientific community is centred
on a nucleus of scientists from Western countries, with
the most intense global collaborations taking place
among the United States, United Kingdom and Canada.
The presence and influence that these countries have on
biomedical research [64–66] may be due to their large
multi-stakeholder research partnerships, greater financial
investment in clinical research, and high population of
active scientists and research centres compared to other
countries.
Publication activity worldwide shows that low- and
middle-income countries have low levels of articles in
high-IF medical journals. Difficulties in healthcare, edu-
cation and research systems, information access and
communication, language barriers and economic and
Table 5 Most frequent funding institutions
Funding institution and
country
Funding
type
Articles Citations Citations
per
article
Articles in
collaboration
Journals Main journals (number of articles)
National Institutes of Health
(NIH), United States
Non-industry 7422 1,312,297 176.8 2187 39 Journal of Clinical Oncology (1096), The New
England Journal of Medicine (869), JAMA (614)
Hoffmann-La Roche,
Switzerland
Industry 1188 218,428 183.9 997 36 The New England Journal of Medicine (159),
Journal of Clinical Oncology (155), Lancet
Oncology (96)
Pfizer, Inc., United States Industry 1139 197,275 173.2 1001 36 The New England Journal of Medicine (187),
JACC (112), Journal of Clinical Oncology (82)
Merck Sharp & Dohme
(MSD), United States
Industry 1097 189,047 172.3 978 35 The New England Journal of Medicine (156),
JACC (145), Diabetes Care (116)
Novartis, Switzerland Industry 1052 192,229 182.7 900 34 The New England Journal of Medicine (157),
JACC (107), Journal of Clinical Oncology (81)
Sanofi, France Industry 987 170,078 172.3 920 34 JACC (152), Diabetes Care (142), The New
England Journal of Medicine (135)
AstraZeneca, United
Kingdom
Industry 938 168,667 179.8 841 33 JACC (166), The New England Journal of
Medicine (131), Diabetes Care (101)
GlaxoSmithKline, United
Kingdom
Industry 937 174,377 186.1 832 35 The New England Journal of Medicine (154),
JACC (95), Diabetes Care (88)
Bristol-Myers Squibb (BMS),
United States
Industry 924 186,731 202.1 843 33 The New England Journal of Medicine (141),
JACC (121), Diabetes Care (119)
Johnson & Johnson,
United States
Industry 873 153,063 175.3 791 34 The New England Journal of Medicine (136),
JACC (113), Diabetes Care (90)
Abbott Laboratories,
United States
Industry 843 141,475 167.8 758 33 JACC (218), The New England Journal of
Medicine (129), Diabetes Care (71)
Eli Lilly and Company,
United States
Industry 796 118,087 148.4 727 29 Diabetes Care (144), JACC (133), The New
England Journal of Medicine (88)
Boehringer Ingelheim,
Germany
Industry 600 125,626 209.4 537 31 The New England Journal of Medicine (115),
Diabetes Care (89), JACC (78)
Medtronic, United States Industry 565 95,746 169.5 525 25 JACC (186), The New England Journal of
Medicine (84), Diabetes Care (65)
National Institute of
Health Research (NIHR),
United Kingdom
Non-industry 502 42,358 84.4 409 40 The Lancet (76), The BMJ (66), The New England
Journal of Medicine (35)
Amgen Inc., United States Industry 488 83,923 172.0 424 25 The New England Journal of Medicine (88),
Journal of Clinical Oncology (65), JACC (64)
Bayer AG, Germany Industry 487 107,327 220.4 453 33 The New England Journal of Medicine (89), JACC
(84), Circulation (42)
Medical Research Council
(MRC), United Kingdom
Non-industry 426 67,256 157.9 304 39 The Lancet (84), The BMJ (47), The New England
Journal of Medicine (29)
Takeda Pharmaceutical
Company, Japan
Industry 392 83,259 212.4 354 28 Diabetes Care (71), The New England Journal of
Medicine (70), JACC (44)
National Health and
Medical Research
Council (NHMRC), Australia
Non-industry 338 35,116 103.9 276 38 Diabetes Care (34), The New England Journal of
Medicine (34), The Lancet (34)
Daiichi Sankyo Company,
Japan
Industry 336 52,054 154.9 325 18 JACC (105), Diabetes Care (46), The New England
Journal of Medicine (43)
Boston Scientific
Corporation, United States
Industry 317 45,609 143.9 291 14 JACC (140), Circulation (58), European Heart
Journal (38)
Novo Nordisk, Denmark Industry 306 44,994 147.0 273 26 Diabetes Care (162), The New England Journal of
Medicine (38), The Lancet (24)
Gilead Sciences,
United States
Industry 301 53,978 179.3 244 22 The New England Journal of Medicine (67),
JACC (49), Hepatology (26)
Wellcome Trust,
United Kingdom
Non-industry 276 32,785 118.8 142 36 The Lancet (67), The BMJ (34),
PLOS Medicine (26)
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Table 5 Most frequent funding institutions (Continued)
Funding institution and
country
Funding
type
Articles Citations Citations
per
article
Articles in
collaboration
Journals Main journals (number of articles)
Canadian Institutes of
Health Research (CIHR),
Canada
Non-industry 266 27,300 102.6 216 30 The New England Journal of Medicine (46), JAMA
(29), The Lancet (22)
Cancer Research UK,
United Kingdom
Non-industry 229 23,766 103.8 202 21 Lancet Oncology (64), Journal of Clinical
Oncology (45), Annals of Oncology (27)
Allergan plc, Ireland Industry 203 32,028 157.8 195 26 American Journal of Psychiatry (39), The New
England Journal of Medicine (27), JACC (18)
Servier, France Industry 199 33,106 166.4 194 20 JACC (51), The New England Journal of Medicine
(29), European Heart Journal (24)
Astellas Pharma Inc., Japan Industry 193 38,282 198.4 178 29 The New England Journal of Medicine (38),
European Urology (18), JACC (16)
Teva Pharmaceutical
Industries Ltd., Israel
Industry 175 29,128 166.4 167 24 The New England Journal of Medicine (29),
Lancet Neurology (20), Journal of Allergy and
Clinical Immunology (18)
The Medicines Company,
United States
Industry 175 26,314 150.4 165 10 JACC (76), Circulation (29), The New England
Journal of Medicine (28)
Eisai Co., Ltd., Japan Industry 161 36,321 225.6 150 22 The New England Journal of Medicine (34),
JACC (30), Circulation (16)
Merck KGaA, Germany Industry 156 35,146 225.3 134 20 The New England Journal of Medicine (24),
Annals of Oncology (21), Lancet Oncology (20)
Otsuka Pharmaceutical
Co., Ltd., Japan
Industry 138 21,029 152.4 130 20 JACC (31), American Journal of Psychiatry (31),
The New England Journal of Medicine (14)
Bill & Melinda Gates
Foundation, United States
Non-industry 135 15,839 117.3 95 15 The Lancet (33), PLOS Medicine (27), The New
England Journal of Medicine (24)
Celgene Corporation,
United States
Industry 134 26,369 196.8 102 19 Journal of Clinical Oncology (31), The New
England Journal of Medicine (26), Blood (20)
Federal Ministry of
Education and Research
(BMBF), Germany
Non-industry 119 11,409 95.9 104 28 Journal of Clinical Oncology (14), Blood (10),
Diabetes Care (9)
UCB, Belgium Industry 118 16,085 136.3 100 14 Annals of the Rheumatic Diseases (47), Lancet
Neurology (14), The New England Journal of
Medicine (13)
Biotronik, Germany Industry 104 15,554 149.6 96 7 JACC (44), European Heart Journal (22), The New
England Journal of Medicine (19)
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disadvantages) for productivity in low- and middle-
income regions. In addition, restrictions and difficulties
in conducting clinical research in resource-poor situa-
tions result in the exclusion of many of these countries
from the planning, conduct and publication of RCTs
[67–69]. As might be expected, our results support
previous findings that low- and middle-income countries
[31, 70, 71] had minimal contributions in articles pub-
lished in major medical journals. For example, a previ-
ous study [70] showed that most of the authors of
original papers published in five high-impact general
medical journals (including The New England Journal of
Medicine, The Lancet, JAMA, The BMJ and Annals of In-
ternal Medicine) were more frequently affiliated with
institutions in the same country as the journal. To
address some of these problems, scientists, institutionsand funders should promote collaborations (beyond his-
torical, cultural and political factors) to share knowledge,
expertise and innovative methodologies for clinical
research. This may involve partnerships with Western
countries to support capacity and resource development
and research training.
RCT-related articles were published most often in high
IF medical journals devoted to general and internal
medicine, cardiology and oncology (nearly 57% of all
articles). Similarly, the lists of the most cited articles
identified topics which reflect major advances in the
management of chronic conditions (such diabetes,
cardiovascular disorders and cancer). The large relative
productivity in general internal medicine, cardiology and
oncology may be explained by the important role of
randomised evidence to novel treatments and preventive
strategies for these chronic diseases. In line with previous
Table 6 Most cited articles
Rank Articles Article type Total
citations
Citations
per year
1. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical
measurement. Lancet. 1986;1(8476):307–10. PubMed PMID: 2868172.
Methods 30,217 974.7
2. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P,
Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the
development and progression of long-term complications in insulin-dependent diabetes mellitus. N
Engl J Med. 1993;329(14):977–86. PubMed PMID: 8366922.
Original
research
11,618 484.1
3. UK Prospective Diabetes Study (UKPDS) Group, Turner RC, Holman RR, Cull CA, Stratton IM, Matthews
DR, Frighi V, Manley SE, Neil A, McElroy K, Wright D, Kohner E, Fox C, Hadden D, Mehta Z, Smith A,
Nugent Z, Peto R. Intensive blood-glucose control with sulphonylureas or insulin compared with con-
ventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.
1998;352(9131):837–53. PubMed PMID: 9742976.
Original
research
9895 520.8
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford
SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women’s Health Initiative
Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women:
principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–
33. PubMed PMID: 12117397.
Original
research
8962 597.5
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Pre-
vention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle interven-
tion or metformin. N Engl J Med. 2002;346(6):393–403. PubMed PMID: 11832527.
Original
research
8878 591.9
6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi
C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG,
Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain
Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;
352(10):987–96. PubMed PMID: 15758009.
Original
research
8017 668.1
7. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgeirsson G, Pyorala K, Miettinen T,
Wilhelmsen L, Olsson AG, Wedel H, Kristianson K, Thomsen H, Nordero E, Thosen B, Lyngborg K.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the
Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9. PubMed PMID: 7968073.
Original
research
7924 344.5
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. PubMed PMID: 15175435.
Original
research
6835 525.8
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J,
Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for meta-
static breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. PubMed PMID: 11248153.
Original
research
6507 406.7
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ; West of
Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in
men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301–7. PubMed PMID: 7566020.
Original
research
5933 269.7
11. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C,
Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP,
Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ,
Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma.
N Engl J Med. 2010;363(8):711–23. PubMed PMID: 20525992.
Original
research
5884 840.6
12. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies
R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events
in high-risk patients. N Engl J Med. 2000;342(3):145–53. PubMed PMID: 10639539.
Original
research
5761 338.9
13. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, Marler JR, Brott T, Bro-
derick J, kothari R, Odonoghue M, Barsan W, Tomsick T, Spilker J, Miller R, Sauerbeck L, Jarrell J, Kelly J,
Perkins T, McDonald T, Rorick M, Hickey C, Armitage J. Tissue plasminogen activator for acute ischemic
stroke. N Engl J Med. 1995;333(24):1581–7. PubMed PMID: 7477192.
Original
research
5533 251.5
14. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi
S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group.
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose
tolerance. N Engl J Med. 2001;344(18):1343–50. PubMed PMID: 11333990.
Original
research
5519 344.9
15. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-
Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis
and septic shock. N Engl J Med. 2001;345(19):1368–77. PubMed PMID: 11794169.
Original
research
5285 330.3
16. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P,
Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–67.
Original
research
5258 328.6
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citations
Citations
per year
PubMed PMID: 11,794,168.
17. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner
A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D,
Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in
advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. PubMed PMID: 18650514.
Original
research
5228 580.0
18. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM,
Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction
in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl
J Med. 1996;335(14):1001–9. PubMed PMID: 8801446.
Original
research
5205 247.9
19. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF
Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a rando-
mised placebo-controlled trial. Lancet. 2002;360(9326):7–22. PubMed PMID: 12114036.
Original
research
5041 336.1
20. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E,
Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD,
Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with
atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. PubMed PMID: 19717844.
Original
research
4975 621.9
21. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of
spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone
Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17. PubMed PMID: 10471456.
Original
research
4948 274.9
22. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M,
Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treat-
ment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65. PubMed PMID: 11583749.
Original
research
4757 297.3
23. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr., Häussinger D, Diago M, Carosi
G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis
C virus infection. N Engl J Med. 2002;347(13):975–82. PubMed PMID: 12324553.
Original
research
4740 316.0
24. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D,
Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal
volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):
1301–8. PubMed PMID: 10793162.
Original
research
4633 272.5
25. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L,
Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDo-
nald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1
antibody in cancer. N Engl J Med. 2012;366(26):2443–54. PubMed PMID: 22658127.
Original
research
4512 902.4
26. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr., Cuddy TE, Davis BR, Geltman EM, Goldman S,
Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH; The SAVE
Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction
after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;
327(10):669–77. PubMed PMID: 1386652.
Original
research
4437 177.5
27. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus
progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and
Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605–13. PubMed PMID:
9718051.
Original
research
4325 227.6
28. North American Symptomatic Carotid Endarterectomy Trial Collaborators, Barnett HJM, Taylor DW,
Haynes RB, Sackett DL, Peerless SJ, Ferguson GG, Fox AJ, Rankin RN, Hachinski VC, Wiebers DO, Eliasziw
M. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid sten-
osis. N Engl J Med. 1991;325(7):445–53. PubMed PMID: 1852179.
Original
research
4315 166.0
29. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B,
Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA,
Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;
361(10):947–57. PubMed PMID: 19692680.
Original
research
4261 532.6
30. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent
Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary
syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502. PubMed PMID: 11519503.
Original
research
4176 261.0
31. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM,
Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular
outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.
PubMed PMID: 11565518.
Original
research
4164 260.3
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32. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic
nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456–62. PubMed PMID: 8413456.
Original
research
3965 165.2
33. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A,
Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood
JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3
Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J
Med. 2011;364(26):2507–16. PubMed PMID: 21639808
Original
research
3952 658.7
34. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj
S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara
P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-
small-cell lung cancer. N Engl J Med. 2005;353(2):123–32. PubMed PMID: 16014882.
Original
research
3923 326.9
35. CAPRIE Steering Committee, Gent M, Beaumont D, Blanchard J, Bousser MG, Coffman J, Easton JD, Hampton
JR, Harker LA, Janzon L, Kusmierek JJ, Panak E, Roberts RS, Shannon JS, Sicurella J, Tognoni G, Topol EJ,
Verstraet M, Warlow C, Cairns JA, Chesebro JH, von der Lippe G, Ross Russell RW, Wolf PA, Boissel JP,
Friedman L, Fuster V, Harrison MG, Pocock S, et al. A randomised, blinded, trial of clopidogrel versus aspirin in
patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–39. PubMed PMID: 8918275.
Original
research
3902 185.8
36. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of
cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973–9. PubMed PMID: 9077376.
Original
research
3874 193.7
37. UK Prospective Diabetes Study (UKPDS) Group, Turner RC, Holman RR, Stratton IM, Cull CA, Matthews
DR, Frighi V, Wright D, Neil A, Kohner E, McElroy K, Fox C, Hadden D, et al. Effect of intensive blood-
glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS
34). Lancet. 1998;352(9131):854–65. PubMed PMID: 9742977.
Original
research
3861 203.2
38. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW,
Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic
implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N
Engl J Med. 2002;346(12):877–83. PubMed PMID: 11907286.
Original
research
3822 254.8
39. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP,
Goff DC Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr., Probstfield JL,
Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J
Med. 2008;358(24):2545–59. PubMed PMID: 18539917.
Original
research
3791 421.2
40. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H,
Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hyper-
tension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study
Group. Lancet. 1998;351(9118):1755–62. PubMed PMID: 9635947.
Original
research
3773 198.6
41. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel
carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):
2542–50. PubMed PMID: 17167137.
Original
research
3772 342.9
42. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A,
Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of
breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Can-
cer Inst. 1998;90(18):1371–88. PubMed PMID: 9747868.
Original
research
3757 197.7
43. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE,
Helterbrand JD, Ely EW, Fisher CJ Jr.; Recombinant human protein C Worldwide Evaluation in Severe
Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for se-
vere sepsis. N Engl J Med. 2001;344(10):699–709. PubMed PMID: 11236773.
Original
research
3757 234.8
44. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W,
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and reported, sometimes serving financial rather than pub-
lic interests [78]. Given that research funding is often re-
stricted, the scientific community is responsible for using
the available resources most efficiently when exploring re-
search priorities to afford knowledge users and population
health needs [76, 77, 79, 80].
Our findings suggest that women are vastly underrepre-
sented in the group of most prolific scientists publishingin high-impact medical journals. This is in direct contrast
to recent studies that have identified a gender gap in re-
search publications [81–84]. For example, a previous study
[84] showed that women in first authorship positions in-
creased from 27% in 1994 to 37% in 2014 in leading med-
ical journals (including Annals of Internal Medicine,
JAMA Internal Medicine, The BMJ, JAMA, The Lancet
and The New England Journal of Medicine), but progress
has plateaued or declined since 2009. An urgent need ex-
ists to investigate the underlying causes of the potential
gender gap to help identify publication practices and strat-
egies to increase women’s influence [82, 84].
Several limitations exist in our study. First, we char-
acterised the knowledge structures generated by a
large number of articles published in major medical
journals that are included in the WoS database.
Table 7 Most prolific journals and most commonly used keywords per journal
Journal subject category Total
articles
Journal name Total
articles
Keywords Total
articles
General medical journals 13,688 The Lancet 3593 Clinical trial 331
Therapy 310
Efficacy 175
Management 167
Risk 164
The New England Journal of Medicine 3275 Clinical trial 875
Randomised controlled trial 511
Therapy 385
Double-blind 238
Risk 201
The BMJ 2516 Clinical trial 151
Management 109
Intervention 96
Therapy 88
Risk 77
JAMA 1904 Clinical trial 237
Therapy 153
Risk 136
Meta-analysis 130
Double-blind 127
JAMA Internal Medicine 1122 Clinical trial 151
Risk 98
Randomised controlled trial 93
Intervention 84
Cardiovascular disease 81
Annals of Internal Medicine 1097 Clinical trial 140
Therapy 96
Risk 75
Disease 62
Efficacy 55
Specialised medical journals 25,617 Journal of Clinical Oncology 3343 Chemotherapy 1028
Clinical trial 772
Therapy 646
Survival 442
Randomised controlled trial 385
Circulation 2331 Myocardial infarction 690
Clinical trial 618
Cardiovascular disease 578
Therapy 466
Coronary heart disease 454
JAAC – Journal of the American College of Cardiology 2133 Myocardial infarction 355
Clinical trial 345
Cardiovascular disease 281
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Table 7 Most prolific journals and most commonly used keywords per journal (Continued)
Journal subject category Total
articles
Journal name Total
articles
Keywords Total
articles
Mortality 258
Randomised controlled trial 247
Diabetes Care 1885 Diabetes mellitus 779
Glycaemic control 305
Clinical trial 272
Therapy 225
Risk 189
Journal of Allergy and Clinical Immunology 1354 Asthma 446
Children 364
Double-blind 238
Clinical trial 232
Histamine 222
European Heart Journal 1315 Clinical trial 231
Myocardial infarction 228
Mortality 159
Therapy 159
Cardiovascular disease 153
Annals of Oncology 1119 Chemotherapy 448
Clinical trial 353
Therapy 236
Survival 169
Carcinoma 130
American Journal of Respiratory and Critical Care
Medicine
1011 Asthma 316
Clinical trial 270
Therapy 182
Chronic obstructive
pulmonary disease
178
Bronchial
hyperresponsiveness
148
Gastroenterology 1008 Clinical trial 158
Therapy 122
Randomised controlled trial 86
Inflammatory bowel disease 75
Cirrhosis 63
Note: Journals with at least 1000 articles. Keyword data refer to the period 1990–2017
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clinical-trial-related articles published in 40 leading
medical journals. We suspect that these articles repre-
sent those that have great implications for clinical
practice and that are relevant to clinical practice
guidelines and healthcare regulators. Although the
publication production analysed has been drawn from
an exhaustive analysis of the biomedical literature,
possibly, the search missed some relevant articles
(and journals). Some reports may be published injournals without being indexed as RCTs, making them
difficult to identify. Second, as in many bibliometric
analyses, the normalisation of the different names of
an author, country and funding sources is fundamen-
tally important to avoiding potential errors. We con-
ducted a careful manual validation of the references
and textual data to avoid typographical, transcription
and/or indexing errors. However, we recognize this
procedure does not assure complete certainty. Third,
the affiliation addresses of authors do not necessarily
Catalá-López et al. Trials           (2020) 21:34 Page 21 of 24reflect the country where the research was conducted
or the research funding source. Fourth, topical ana-
lysis that extracts a set of unique keywords, word
profiles and co-words may indicate intellectual
organization in publication production, albeit with in-
herent limitations [85, 86]. Fifth, the use of citation
analysis carries some problems [87–91]. A potential
length time-effect bias exists, which puts the more re-
cent articles at a disadvantage. In addition, the bio-
medical literature is rich in barriers and motivations
for publication and citation preferences [87], including
self-citation (bias towards one’s own work) [88], lan-
guage bias (bias towards publishing and citing English
articles), omission bias (bias whereby competitors are
purposely not cited), and selective reporting and pub-
lication bias (bias in which “negative” results are with-
held from publication and citation) [89–92]. In
addition, citations are also treated as equal regardless
of whether research is being cited for its positive con-
tribution to the field or because it is being criticized.
Finally, our methods represent only a mapping ap-
proach, which could be complemented further by
more detailed analyses such as by examining the con-
tent (e.g. differences in journal or author characteris-
tics between publicly funded and industry-funded
studies, designs/methodology, etc.), the reporting and
the reproducible research practices through research
of research (“meta-research”) studies [92–98].
Conclusion
The global analysis presented in this study provides
evidence of the scientific growth of RCT- related articles
published in high-IF medical journals. Over the last 50
years, publication activity in leading medical journals has
increased, with Western countries (most notably, the
United States) leading but with low- and middle-income
countries showing very limited representation. Our ana-
lysis contributes to a better conceptualization and
understanding of RCT articles and identified the main
areas of research, the most influential publication
sources chosen for their scientific dissemination and the
major scientific leaders. Given the dynamic nature of the
field, whether the growth trend remains the same in the
coming years and how the characteristics of the field
change over time will be interesting to see.
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